Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Ferreri AJM, et al. Among authors: thurner l. Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13. Leukemia. 2022. PMID: 35562406 Clinical Trial.
Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.
Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M. Thurner L, et al. Blood. 2018 Dec 27;132(26):2744-2753. doi: 10.1182/blood-2018-03-836932. Epub 2018 Sep 24. Blood. 2018. PMID: 30249786 Free article.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: thurner l. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Current Treatment Options in CLL.
Bewarder M, Stilgenbauer S, Thurner L, Kaddu-Mulindwa D. Bewarder M, et al. Among authors: thurner l. Cancers (Basel). 2021 May 19;13(10):2468. doi: 10.3390/cancers13102468. Cancers (Basel). 2021. PMID: 34069354 Free PMC article. Review.
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa D, Lesan V, Berdel C, Stilgenbauer S, Bewarder M, Thurner L, Witzens-Harig M, Viardot A, Soekler M, Keller U, Truemper L, Christofyllakis K, Fleser O, Bittenbring JT, Poeschel V, Held G, Jagoda P. Kaddu-Mulindwa D, et al. Among authors: thurner l. Leuk Lymphoma. 2022 Feb;63(2):326-334. doi: 10.1080/10428194.2021.1975193. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668817
Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review).
Christofyllakis K, Bittenbring JT, Thurner L, Ahlgrimm M, Stilgenbauer S, Bewarder M, Kaddu-Mulindwa D. Christofyllakis K, et al. Among authors: thurner l. Mol Clin Oncol. 2022 Jan;16(1):21. doi: 10.3892/mco.2021.2453. Epub 2021 Nov 25. Mol Clin Oncol. 2022. PMID: 34909199 Free PMC article. Review.
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Kaddu-Mulindwa D, Gödel P, Kutsch N, Heger JM, Scheid C, Borchmann P, Holtick U, Held G, Thurner L, Bewarder M, Rixecker T, Bittenbring JT. Kaddu-Mulindwa D, et al. Among authors: thurner l. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e498-e506. doi: 10.1016/j.clml.2022.01.007. Epub 2022 Jan 13. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35094950 Review.
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, Held G, Poeschel V, Lesan V, Bittenbring JT, Thurner L, Pfreundschuh M, Christofyllakis K, Truemper L, Loeffler M, Schmitz N, Hoth M, Hallek M, Fischer K, Stilgenbauer S, Bewarder M, Rixecker TM. Kaddu-Mulindwa D, et al. Among authors: thurner l. Lancet Haematol. 2022 Feb;9(2):e133-e142. doi: 10.1016/S2352-3026(21)00369-0. Lancet Haematol. 2022. PMID: 35114151 Clinical Trial.
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.
Yordanova K, Stilgenbauer S, Bohle RM, Lesan V, Thurner L, Kaddu-Mulindwa D, Bittenbring JT, Scharberger M, Aßmann G, Bewarder M. Yordanova K, et al. Among authors: thurner l. Br J Haematol. 2019 Sep;186(6):e203-e207. doi: 10.1111/bjh.16082. Epub 2019 Jul 1. Br J Haematol. 2019. PMID: 31257571 Free article. No abstract available.
Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy.
Rixecker T, Lesan V, Ahlgrimm M, Thurner L, Bewarder M, Murawski N, Christofyllakis K, Altmeyer S, Bick A, Stilgenbauer S, Bittenbring JT, Kaddu-Mulindwa D. Rixecker T, et al. Among authors: thurner l. Bone Marrow Transplant. 2021 Jan;56(1):195-201. doi: 10.1038/s41409-020-01003-0. Epub 2020 Jul 23. Bone Marrow Transplant. 2021. PMID: 32704092
78 results